Raymond James Financial’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Raymond James Financial’s Portfolio GNOM Stock Details GNOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$484K	Sell	8,515 -787	-8%	-$37.5K	﹤0.01%	4524
2026 Q1	$407K	Buy	9,302 +2,122	+30%	+$98.1K	﹤0.01%	4486
2025 Q4	$326K	Buy	+7,180	New	+$318K	﹤0.01%	4519
2025 Q3	–	Sell	-5,474	Closed	-$185K	–	5674
2025 Q2	$185K	Sell	5,474 -3,924	-42%	-$124K	﹤0.01%	4556
2025 Q1	$299K	Sell	9,398 -67,175	-88%	-$2.55M	﹤0.01%	4222
2024 Q4	$2.97M	Buy	+76,573	New	+$3.22M	﹤0.01%	2679

Other funds holding GNOM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

OAM

Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return

AAP

Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

CFD

Creative Financial Designs Kokomo, Indiana $2.1B AUM 23.1% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

FIA

Foundations Investment Advisors Phoenix, Arizona $9.72B AUM 29.41% 1-Year Est. Return

Raymond James Financial's GNOM Position: Q2 2026 in Review

Raymond James Financial reduced its Global X Genomics & Biotechnology ETF (GNOM) stake by 8.5% in Q2 2026, selling an estimated $37.5K and leaving 8,515 shares worth $484K. The position accounts for ﹤0.01% of the portfolio, ranked #4524.

Raymond James Financial first reported a position in GNOM in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.97M in Q4 2024. 48 funds tracked by Wall St. Rank hold GNOM as of Q2 2026.

Raymond James Financial held 8,515 shares of Global X Genomics & Biotechnology ETF worth $484K as of Q2 2026.
Raymond James Financial sold 787 Global X Genomics & Biotechnology ETF shares in Q2 2026, an estimated $37.5K.
Global X Genomics & Biotechnology ETF made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #4524 holding.
Raymond James Financial first reported a position in Global X Genomics & Biotechnology ETF in Q4 2024 and has held it in 6 quarters since.
Raymond James Financial's Global X Genomics & Biotechnology ETF position peaked at $2.97M in Q4 2024.
48 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.